Industry Movers: DSM, Hofseth and ANSES
We start with DSM Nutritional Products (DNP) and the news that the firm’s President & CEO is to retire.
Effective from 1 April 2021, Goppelsroeder ends his stint at DSM having joined in 2003 when DSM acquired Roche Holding AG’s vitamins division. Dimitri de Vreeze, DSM’s Co-CEO will make the leap into the DNP leadership role in his capacity as COO.
Along with co-CEO Geraldine Matchett, de Vreeze said, “Goppelsroeder has been a key and valued leader for DSM and we are very grateful for his dedication and the contributions he has made in transforming DSM to where we are today.
“We will be sad to say goodbye to a great colleague and friend who has built a fantastic leadership team. Chris leaves a tremendous legacy, and on behalf of the entire company, we wish him all the best for his well-deserved retirement.”
Goppelsroeder became DNP’s President & CEO in 2013, where he oversaw the group’s recent acquisitions of Glycom and Erber Group.
He also played a crucial role in the development projects such as Clean Cow/Bovaer, Veramaris and DSM’s new moves in the space of precision and personalised nutrition.
Hofseth BioCare
At the start of this month, marine raw material specialists Hofseth BioCare (HBC) moved to secure the services of former Head of Sales and Marketing, Health Ingredients at Lonza, Reto Renggli.
As the Norwegian’s firm’s new Vice President within HBC’s Consumer Health Division, Renggli has the task of helping to expand the firm’s expansion across the consumer health sector and the creation of a global distribution network for its range of products and ingredients.
HBC’s product range includes ProGo, a salmon protein hydrolysate, OmeGo an unrefined salmon oil produced from Norwegian Atlantic salmon at the firm’s plant on the Western coast of Norway and CalGo, a powder produced from salmon bones that may help increase bone density and bone deposition in older individuals.
“I was inspired to join HBC’s senior leadership team by the global opportunity I see for this rapidly growing biotech business,” says Renggli.
“As we accelerate plans to commercialise and expand HBC’s product and ingredient ranges, our skills and experience are set to prove complementary.”
Renggli’s appointment follows the appointment of Andy Gill, formerly of GSK and Novartis, who became HBC’s Vice President of Consumer Healthcare last month.
HBC also welcome ex-Johnson & Johnson. Will Urban-Smith, as HBC’s new Vice President within its Consumer Health Division this month.
ANSES appointment
Finally, Matthieu Schuler becomes The French Agency for Food, Environmental and Occupational Health & Safety’s (ANSES) new Managing Director General of the agency’s "Science for Expertise" Division.
Matthieu Schuler takes over from Professor Gérard Lasfargues with a mandate to coordinate the departments responsible for risk assessment, health alerts and vigilance, scientific research funding, and the "Social Sciences, Expertise and Society" unit.
In conjunction with the ANSES Scientific Board, he will be responsible for the robustness of the scientific processes implemented by the Agency.
“Faced with the extreme diversity of our fellow citizens' concerns regarding the risks for humankind, the planet and its ecosystems, the mobilisation of science to bolster expert opinion must address three major challenges,” comments Schuler.
“First of all, we must methodically take into account the latest available knowledge to characterise risks, prioritise them and propose ways of mitigating them in the short and medium term. Then, through dialogue with all stakeholders – civil society, economic actors, public authorities – encourage all concerned to act to reduce these risks within their own areas of responsibility.
“Finally, while listening carefully to the vigilance schemes and research challenges raised by expert appraisal, promote the emergence of new data and knowledge to build tomorrow's global health and safety system with our European and international counterparts,” he adds.
